Nicotine dihydrochloride | 6019-02-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Nicotine dihydrochloride
• 英文别名: 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine;dihydrochloride
• CAS: 6019-02-9
• 化学式: C10H16Cl2N2
• 分子量: 235.15
• InChiKey: MQWJVKLIBZWVEL-XRIOVQLTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.69
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES<br/>[FR] SELS, CO-CRISTAUX, ET COMPLEXES DE CO-CRISTAUX DE SELS DE NICOTINE
  申请人：REYNOLDS TOBACCO CO R

  公开号：WO2015183801A1

  公开（公告）日：2015-12-03

  The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

  该发明提供了某些尼古丁盐、共晶和盐共晶，并提供了某些尼古丁盐的新颖多形态形式。具体来说，描述了与粘酸、3,5-二羟基苯甲酸和2,3-二羟基苯甲酸结合的尼古丁盐，以及尼古丁4-乙酰氨基苯甲酸、尼古丁吉替酸和尼古丁1-羟基-2-萘酸的结晶多形态形式。该发明还提供了制备和表征这些尼古丁盐、共晶和盐共晶以及其多形态形式的方法。此外，还提供了含有尼古丁盐、共晶和/或盐共晶的烟草制品，包括吸烟物品、无烟烟草制品和电子吸烟物品。
• [EN] NICOTINE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE NICOTINE, ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：GOODMAN JORY F

  公开号：WO2015183530A1

  公开（公告）日：2015-12-03

  This invention provides a compound selected from the group consisting of L- nicotine(X1)(X2) and D-nicotine(X1)(X2), or a pharmaceutically acceptable salt thereof, wherein (i) each of Χ1 and X2 is independently a pharmaceutically acceptable anion or a null set; and (ii) Χ1 and X2 cannot both be null sets. This invention also provides related compositions, as well as methods for treating a disorder reasonably believed to be ameliorated by the administration of nicotine.

  本发明提供了一种化合物，所选自组中包括L-尼古丁（X1）（X2）和D-尼古丁（X1）（X2），或其药学上可接受的盐，其中（i）Χ1和X2各自独立地是药学上可接受的阴离子或空集；（ii）Χ1和X2不能同时为空集。本发明还提供了相关的组合物，以及治疗通过尼古丁治疗合理地认为能够改善的疾病的方法。
• NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES
  申请人：R.J. Reynolds Tobacco Company

  公开号：US20150344456A1

  公开（公告）日：2015-12-03

  The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

  本发明提供了某些尼古丁盐、共晶、盐共晶，并提供了某些尼古丁盐的新型多晶形式。具体而言，本发明描述了与粘酸、3,5-二羟基苯甲酸和2,3-二羟基苯甲酸共晶的尼古丁盐，以及尼古丁4-乙酰氨基苯甲酸盐、尼古丁吉替酸盐和尼古丁1-羟基-2-萘酸晶体多晶形式。本发明进一步提供了制备和表征这种尼古丁盐、共晶和盐共晶及其多晶形式的方法。此外，本发明还提供了含有尼古丁盐、共晶和/或盐共晶的烟草产品，包括吸烟物品、无烟烟草产品和电子吸烟物品。
• Tobacco substitute
  申请人：UNIVERSITY OF UTAH RESEARCH FOUNDATION

  公开号：EP0745380A2

  公开（公告）日：1996-12-04

  The present invention relates generally to a ciagrette substitute for administering a dose of nicotine. More specifically, the present invention is directed to a nicotine-containing dosage-form comprising a holder member which may be used as part of an effective smoking cessation program or in situations where smoking is undesirable or not permitted. The dosage form is configured as a dosage form having a nicotine-containing composition attached to a holder member. Nicotine is released from the dosage form and absorbed through the intra-oral mucosal surfaces as the nicotine-containing composition releases nicotine within a user's mouth. The holder member facilitates insertion and removal of the dosage form into and out of a user's mouth. The user can selectively insert and remove the dosage form as desired to selectively control the release of nicotine. In addition, the user can insert and remove the dosage form in a manner which meets the user's psychological need or desire for ritualistic oral stimulation similar to cigarette smoking.

  本发明总体上涉及一种用于给药尼古丁剂量的咀嚼替代物。更具体地说，本发明涉及一种含有尼古丁的剂型，该剂型包括一个支架部件，可用作有效戒烟计划的一部分，或在不希望或不允许吸烟的情况下使用。该剂型被配置为一种剂型，其含尼古丁的组合物附着在支架部件上。当含尼古丁的组合物在使用者口腔内释放尼古丁时，尼古丁从剂型中释放出来并通过口腔内粘膜表面被吸收。夹持件便于将剂型插入和取出使用者的口腔。使用者可以根据需要选择性地插入和取出剂型，以选择性地控制尼古丁的释放。此外，使用者还可以根据自己的心理需要或愿望，插入和取出药剂，以获得类似于吸烟的口腔刺激。
• Orally Dissolving Films
  申请人：Glaxosmithkline LLC

  公开号：EP2446881A1

  公开（公告）日：2012-05-02

  Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein.

  本文公开了可在口腔中快速释放活性剂的快速溶解口服膜制剂，特别是含有尼古丁活性成分的快速溶解口服膜，这种口服膜可实现良好的经颊囊吸收，并可缓解人们对尼古丁的渴望。